Citations

Clear

572 citation(s) found for "Silva, P".

Blocking RAN translation without altering repeat RNAs rescues C9ORF72 -related ALS and FTD phenotypes
Jiang, Xin , Schaeffer, Laure, Patni, Divya, Russo, Tommaso , Lee, Chao-Zong, Aguilar, Corey, Marques, Christine , Jansen-West, Karen, Hruška-Plocháň, Marián , Ray-Soni, Ananya, Lim, Su Min , Held, Aaron , Yue, Mei, Otero, Paula Castellanos, Aryal, Sandeep , Beaussant, Hortense D. A. M. , Basu, Himanish , Takakuwa, Hiro , Daughrity, Lillian M. , Ramesh, Nandini , Costa, Paulo J. da, Quadros, Ana Rita A. A., Nolan, Matthew , Reyes, Charles Jourdan , Wheeler, Hayden J., Moran, Laura C. , Griesman, Grant , Wymann, Benjamin , Trombetta, Bianca A. , Lopez-De-Silanes, Emma Sofia , Canori, Michael, Silva, Yasmim Vieira Souza Da, Eriani, Gilbert , Albers, Mark W. , Arnold, Steven E. , Song, Yuyu , Jain, Ankur, Chiu, I., Zhang, Yong-Jie, Gao, Fen‐Biao , Wainger, Brian J. , Polymenidou, Magdalini , Petrucelli, Leonard, Martin, Franck , Lagier-Tourenne, Clotilde, Lagier‐Tourenne, Clotilde , Jansen-West, Karen R , Castellanos Otero, Paula, Da Costa, Paulo , A A Quadros, Ana Rita , Eriani, Gilbert , Albers, Mark W , Arnold, Steven E , Song, Yuyu , Chiu, Isaac M , Zhang, Yong-Jie , Gao, Fen-Biao , Wainger, Brian J , Polymenidou, Magdalini , Petrucelli, Leonard , Martin, Franck , Lagier-Tourenne, Clotilde , Lee, Chao-Zong , Jansen‐West, Karen , Ray-Soni, Ananya, Krishnan, Gopinath , Jain, Ankur , Petrucelli, Leonard

Mayo Clinic

Science | February 5, 2026 | Volume: 391 | Issue: 6785 | Pages: No page available

10.1126/science.adv2600 | PMID 41643021 Get It

GGGGCC (G 4 C 2 ) repeat expansion in C9ORF72 is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Toxicity is thought to result from the accumulation of either repeat RNAs and/or dipeptide repeat proteins (DPRs) translated from repeat-containing transcripts through repeat-associated non-AUG (RAN) translation. To disentangle RNA from DPR toxicity, we mutated a CUG codon predominantly used to initiate DPR translation from all three reading frames. This mutation disrupted DPR synthesis while preserving the expression of repeat-containing RNAs. Despite the accumulation of RNA foci, behavioral deficits and pathological abnormalities, including p-TDP-43 inclusions, STING activation, motor neuron loss, neuroinflammation, and increased plasma neurofilament concentration, were alleviated in C9ORF72 mice. Base editing of the CUG codon also improved molecular phenotypes and survival in patient induced pluripotent stem cell–derived neurons, which highlights the potential of therapeutically targeting DPR production rather than repeat RNAs.
AI-ECG performance in detecting left ventricular systolic dysfunction and predicting death in Chagas disease patients: SaMi-Trop project
Mangold, K E, Silva, J L P , Sabino, E C , Oliveira, C D, Oliveira, L C, Nunes, M C P, Colossimo, E A, Vinhal, W C, Goncalves, A C O, Attia, I Z, Lopes-Jimenez, F, Ribeiro, A L P, Cardoso, Clareci Silva , Ferreira, Ariela Mota , Colosimo, Enrico A. , Perel, Pablo , Vinhal, Wanessa , Attia, Zachi I. , Lopes-Jimenez, Francisco, Ribeiro, Antonio Luiz

Mayo Clinic

European Heart Journal | February 5, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.4411 Get It

Abstract Background Ventricular systolic dysfunction (LVSD) is the main predictor of mortality in Chagas disease (ChD). Although LVSD can be treated with affordable medications that enhance both symptoms and survival, its diagnosis necessitates advanced imaging tests, which are often unavailable in resource-limited settings. Recently, artificial intelligence (AI) models applied to an electrocardiogram (ECG) have shown promise in detecting LVSD and assessing disease progression, acting as digital biomarkers and offering the potential for screening tools. Purpose This study aims to evaluate the performance of an AI-ECG model in detecting LVSD and predicting mortality in patients with ChD. Specifically, we will fine-tune the AI-ECG model to improve LVSD identification and update the previously published mortality score (JAHA) by replacing NT-proBNP with AI-ECG to assess mortality risk. Methods This study was conducted with patients from the SaMi-Trop project, a prospective cohort of individuals seropositive for ChD from 21 municipalities in Minas Gerais, an endemic region of Brazil. The baseline assessment occurred in 2013–2014, with follow-ups in 2015–2016 (FU1) and 2022–2023 (FU2). The AI-ECG model was fine-tuned using a dataset with an 8% low ejection fraction prevalence. The model was trained with a binary cross-entropy loss function, a batch size of 128, and an Adam optimizer with a learning rate of 0.001. The area under the curve (AUC) was calculated for validation. The fine-tuned model, parsed into 2-second ECG windows, was applied to two waves of the SaMi-Trop cohort: Baseline (4,701 ECGs from 1,906 patients) and FU1 (2,324 ECGs from 1,059 patients). The association between AI-detected LVSD (AI-LVSD) and mortality was assessed using Cox proportional hazard models. Results The fine-tuned AI-LVSD model achieved an AUC of 0.88 (95% CI: 0.78–0.97) in detecting LVSD. When updating the JAHA mortality score, AI-LVSD replaced NT-proBNP with a stronger association with mortality risk, yielding hazard ratios (HR) of 4.5 (95% CI: 3,0–6.8) for two-year mortality and 4.3 (95% CI: 3.4–5.5) for overall mortality. Additionally, when incorporated into a simplified hazard model alongside age and NYHA class, AI-LVSD emerged as a strong biomarker for mortality risk, with hazard ratios of 5.4 (95% CI: 3.7–7.8) for two-year mortality and 4.9 (95% CI: 4.0–6.1) for overall mortality (Figure 1). Conclusion The AI-ECG model accurately identified LVSD for screening purposes and effectively replaced NT-proBNP in a simplified mortality risk model for Chagas disease. This tool can potentially enhance early detection and risk stratification, particularly in remote areas with limited access to advanced diagnostic resources.Figure 01.Cox proportional hazard model
Distal Tibiofibular Syndesmosis: Anatomy, Biomechanics, Imaging Approach, and Postoperative Evaluation
Silva, Lucas N. M. da , Morimoto, Letícia R. , Watanabe, Gustavo G., Rhodes, Nicholas G. , Cruz, Isabela A. N. da , Arruda, Pedro H. C., Netto, Cesar C. de, Mansur, Nacime S. B., Nico, Marcelo A. C. , Guimarães, J P , Filho, Alípio G. Ormond, Morimoto, Letícia R. , Nico, Marcelo Astolfi Caetano , Ormond Filho, Alípio G , Watanabe, Gustavo Oyama, Cruz, Isabela Azevedo Nicodemos da , Arruda, Pedro H. C. , Netto, César de César , Mansur, Nacime Salomão Barbachan , Guimaraes, Júlio B., Filho, Alípio Gomes Ormond

Mayo Clinic

RadioGraphics | January 29, 2026 | Volume: 46 | Issue: 2 | Pages: No page available

10.1148/rg.250065 | PMID 41610035 Get It

Accurate assessment of distal tibiofibular syndesmotic injuries is essential to prevent chronic instability and poor functional outcomes, and conventional radiography, CT, and MRI play complementary and critical roles in the imaging of these injuries.
Regulatory T-cell Sensing of Extracellular ATP via P2RX7 Promotes Their Accumulation and Suppression and Drives Lung Tumor Growth
Santiago-Carvalho, Igor , Francisco, Ronaldo da Silva , Macedo, Bruna de Gois , Salgado, Caio Loureiro , Stoll, Carly R. , Shao, Samantha C. , Beniwal, Angad , Kwok, Tina , Banuelos, Alma , Cione, Marcos Pinheiro , White, Emily , Johnston, Tyler, Leff, Chloe , Silva-Junior, Ildefonso , Souza, Fabio Carvalho de, Thant, Win , Fernandez-Bussy, Sebastian, Abia-Trujillo, David, Vu, Linh H, Husta, Bryan C, Copland, John A. , Gounari, Fotini , Justilien, Verline , Cione, Marcos Vinícios Pinheiro , Francisco, Ronaldo , Macedo, Bruna Gois , Johnston, Tyler M , Leff, Chloe Liliana , Carvalho de Souza, Fabio , Pandya, Prita , D'Império Lima, Maria Regina , Fernandez-Bussy, Sebastian , Abia-Trujillo, David , Vu, Linh H , Tran, Nhan L , Husta, Bryan C , Copland, John A , Gounari, Fotini , Justilien, Verline , Lancaster, Jessica N , Borges da Silva, Henrique , Silva, Ildefonso , Pandya, Prita , Lima, Maria Regina D’Império , Tran, Nhan L. , Lancaster, Jessica N. , Silva, Henrique Borges da

Mayo Clinic

Cancer Immunology Research | January 21, 2026 | Volume: 14 | Issue: 4 | Pages: 658-675

10.1158/2326-6066.cir-25-0567 | PMID 41564348 Get It

Abstract Lung cancer is the leading cause of cancer-related deaths worldwide, and despite advances in treatment, immune suppression remains an obstacle to effective therapy. Effector CD4+ T cells (CD4+ Teff) are critical for antitumor immunity, but their function is often inhibited by regulatory T cells (Treg), which accumulate in lung tumors and mediate suppressive functions through multiple mechanisms. This suppression leads to tumor progression and poor patient outcomes. However, the mechanisms underlying Treg-mediated suppression are not fully understood. Herein, we identify the extracellular adenosine 5-triphosphate receptor P2RX7 as a key regulator of Treg function in lung tumors. In a murine lung cancer model induced by Lewis lung carcinoma cells, we found that P2RX7 enhanced the suppressive capacity of tumor-infiltrating Tregs, promoting tumor growth. In T cell–specific P2RX7-knockout (P2RX7-KO) mice, reduced Treg infiltration was accompanied by increased CD4+ Teff accumulation and improved tumor control. Treg-specific P2RX7-KO mice exhibited reduced tumor growth, confirming a Treg-intrinsic role of P2RX7. Suppression assays revealed that tumor-infiltrating wild-type Tregs had greater suppressive activity compared with P2RX7-KO Tregs, which failed to inhibit type 1 and follicular helper T–like responses. This was associated with increased tumor-specific IgG production by lung B cells in P2RX7-KO mice. We also observed that wild-type Tregs expressed higher levels of the immunosuppressive molecule CTLA-4 when compared with P2RX7-KO Tregs. Thus, we conclude that P2RX7 expression on Tregs is essential for their suppressive function in lung cancer and targeting P2RX7 may constitute a strategy to improve lung cancer treatment by alleviating Treg-mediated immune suppression.
DOP041 Pregnancy and Infant Outcomes After In Utero Exposure to JAK Inhibitors in Inflammatory Bowel Disease: A Global Multicenter Cohort Study
Julsgaard, M, Baunwall, S M, Seow, C, Duricova, D, Kane, S, Zacharias, N, Cremer, A, Kok, K, Kagramanova, A V, Pipek, Barbora , Candido, K, Filip, R, Kiudelis, Vytautas , Pugliese, D, Silva, G Oliveira Santana, Savarino, E V, Smolović, Brigita , Wei, S C, Mahadevan, Uma, Julsgaard, Mette , Seow, Cynthia H., Leong, Rupert W. , Kok, K, Kagramanova, A , Candido, Kristen, Cooney, Rachel , Filip, R, Konečný, M , Paramsothy, Sudarshan , Vieujean, Sophie

Mayo Clinic

Journal of Crohn’s and Colitis | January 21, 2026 | Volume: 20 | Issue: Supplement_1 | Pages: No page available

10.1093/ecco-jcc/jjaf231.078 Get It

Abstract Background JAK inhibitors (JAKi) are small molecules that cross the placenta from early pregnancy.1 Evidence on the safety of in utero JAKi exposure remains limited, particularly regarding pregnancy outcomes, infant infections, vaccine responses, and early development.2, 3 Methods We conducted a multicenter retrospective study within the ECCO CONFER network, including pregnant women with inflammatory bowel disease (IBD) exposed to tofacitinib (TOFA), upadacitinib (UPA), or filgotinib (FILGO). Data were collected from 22 centers across 16 countries and included maternal characteristics, disease activity, medication patterns, and pregnancy and infant outcomes. Results Among 55 JAKi exposed pregnancies, 21 (38.2%) were unplanned and 30 (54.6%) had active disease. Nine women (16.4%) initiated JAKi during pregnancy. Overall, 38 (69.1%) received TOFA, 15 (27.3%) UPA, and 2 (3.6%) FILGO; 39 (70.9%) continued treatment throughout pregnancy. JAKi discontinuation in 1st-2nd trimester led to disease activity in 9/16 cases (56.3%). Maternal complication risk was low: no DVT or (pre) eclampsia occurred; three cases of premature rupture of membranes (GA 34–37) and four required hospitalizations due to infection or other complications. A total of 10 abortions occurred - five spontaneous (9.1%) and five induced (9.1%), including three due to concern about JAKi exposure. Among 45 live births, two infants (3.6%) were preterm, four (7.3%) small for gestational age, and two (3.6%) had Apgar <7 at 5 minutes. No congenital abnormalities were reported. Infant follow-up findings are summarized in Table 1. One-third of breastfeeding women continued JAKi postpartum. A high adherence rate to the national immunization schedule was seen. Eight (19.5%) received the live BCG-vaccine within the first 30 days of life. No adverse events followed live or inactivated vaccines, and no malignancies were observed. Conclusion In this global cohort of JAKi-exposed pregnancies in women with IBD, maternal complication rates were low, and no increased risk of adverse outcomes among live births was identified. While disease activity was common, particularly following discontinuation of JAKi, infant outcomes - including development, infection risk, and vaccine response - were reassuring. These findings provide important preliminary safety data to inform decision-making regarding JAKi use in pregnancy, though prospective studies are needed to confirm long-term safety. References: 1.Fein KC, Arral ML, Kim JS, et al. Placental drug transport and fetal exposure during pregnancy is determined by drug molecular size, chemistry, and conformation. J Control Release 2023;361:29–39. 2.Torres J, Chaparro M, Julsgaard M, et al. European Crohn’s and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation. J Crohns Colitis 2023;17:1–27. 3.Mahadevan U, Seow CH, Barnes EL, et al. Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease. J Crohns Colitis 2025;epub ahead of print. Conflict of interest: Julsgaard, Mette: No conflict of interest Baunwall, Simon MD: No conflict of interest Seow, Cynthia: No conflict of interest Duricova, Dana: No conflict of interest Kane, Sunanda: No conflict of interest Zacharias, Neha: No conflict of interest Leong, Rupert: No conflict of interest Cremer, Anneline: No conflict of interest Kok, Klaartje: No conflict of interest Kagramanova, Anna Valeryevna: No conflict of interest Pipek, Barbora: No conflict of interest Candido, Kristina: No conflict of interest Cooney, Rachel: No conflict of interest Filip, Rafal: No conflict of interest Kiudelis, Vytautas: No conflict of interest Konečný, Michal: No conflict of interest Paramsothy, Sudarshan: No conflict of interest Pugliese, Daniela: No conflict of interest Oliveira Santana Silva, Genoile: Honoraria - Abbvie, Johnson & Johnson, Ferring, Takeda. Research - Abivax, Takeda, Johnson & Johnson, Roche, Sanofi, Polpharma. Advisory board - Abbvie, Johnson & Johnson, MSD. Savarino, Edoardo Vincenzo: No conflict of interest Smolovic, Brigita: No conflict of interest Vieujean, Sophie: No conflict of interest Wei, Shu Chen: No conflict of interest Mahadevan-Velayos, Uma: No conflict of interest
Neoadjuvant immune checkpoint inhibitors (ICIs) for localized dMMR/MSI-h gastroesophageal cancers (GEC): A systematic review with meta-analysis.
Schwengber, Wallace Klein , Silva, Luís Felipe Leite da, Tumelero, Milena, Lenz, Gabriel , Fouchardiere, C. de la, Bekaii-Saab, Tanios S., Pereira, Rafael Alvim , Silva, Luís Felipe Leite da, Tumelero, Milena , Michelon, Isabella , Chung, Kevin, Fouchardière, Christelle de la , Bekaii‐Saab, Tanios , Sonbol, Mohamad Bassam

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 373-373

10.1200/jco.2026.44.2_suppl.373 Get It

373 Background: Recent studies have demonstrated encouraging outcomes with neoadjuvant ICIs in pts with localized deficient mismatch repair (dMMR) and/or microsatellite instability-high (MSI-H) GEC, prompting discussions around the feasibility of nonoperative management (NOM). However, current evidence is largely from phase 1 and 2 clinical trials with limited sample sizes. Thus, the efficacy and safety of neoadjuvant ICI in this pt population remain subject to ongoing debate. Methods: We conducted a systematic review and meta-analysis of prospective and retrospective studies evaluating neoadjuvant ICIs in pts with localized dMMR/MSI-H GEC according to the PRISMA guidelines. The primary outcomes were pathological complete response (pCR) and complete clinical response (cCR) rates. cCR was defined as no evidence of residual disease on tumor-specific imaging and on endoscopy with biopsy. Secondary outcomes included major pathologic response (MPR) rates and the incidence of grade 3–4 immune-related adverse events (irAEs). Proportions with 95% confidence intervals (CI) were used to pool event rates for occurrence of cCR, pCR, MPR and grade 3-4 irAEs. The DerSimonian and Laird random-effects model was used. NOM was assessed as part of the qualitative analysis. Results: 20 studies comprising 396 pts treated with neoadjuvant ICIs were included. Three studies utilized double ICI blockade (PD-1/ PD-L1 inhibitor plus CTLA-4 inhibitor), while the remaining studies primarily utilized monotherapy with a PD-1 inhibitor, with or without chemotherapy. Overall, 320 (81.0%) underwent surgical resection. The pooled pCR rate was 41.6% (95% CI, 33.1%–50.8%), cCR 63.8% (95% CI, 45.6%–78.8%), and MPR 64.2% (95% CI, 49.1%–76.9%). The pooled incidence of grade 3–4 irAEs was 5.1% (95% CI, 0.6%–12.2%). Subgroup analysis showed higher pCR with ≥3 months versus <3 months of ICI (50.2% [95% CI 42.2–58.3] vs 28.4% [18.9–40.2]; χ²=8.69, p=0.003). Forty-four pts were managed with NOM, two experienced early local regrowth over median follow-up ranging from 11.5 to 28 months. Conclusions: Neoadjuvant ICI therapy appears to be a safe and effective therapeutic strategy for pts with localized dMMR/MSI-H GEC. Neoadjuvant ICI exposure for ≥3 months seems to yield higher pCR rates than <3 months. The high and prolonged cCR rates support the nonoperative strategy in selected patients with dMMR/MSI-H GEC.
P-2148. Infection Following Cytokine Release Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy
Nadarevic, Ella, Corraes, Andre De Menezes Silva, Lin, Y., McHugh, Jack , Challener, Douglas W. , Corraes, Andre De Menezes Silva , Vergidis, Paschalis

Mayo Clinic

Open Forum Infectious Diseases | January 12, 2026 | Volume: 13 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofaf695.2311 Get It

Abstract Background Chimeric antigen receptor T-cell therapy (CAR-T) has transformed care for relapsed or refractory B-cell malignancies. Cytokine-release syndrome (CRS) complicates most infusions, yet the ensuing infection risk is ill-defined.Table 1Profile of 230 patients undergoing with CRS following CAR-T therapyTable 2Cytokine Release Syndrome Severity, Management, and Early Outcomes by 90-Day Infection Status Methods CAR-T recipients who developed CRS at our institution from 1 Jan 2018 to 3 June 2024 were retrospectively reviewed. Variables were abstracted into REDCap. CRS was graded with American Society for Transplantation and Cellular Therapy (ASTCT) criteria. All infections occuring after CRS onset to day 90 were adjudicated. Continuous data are reported as medians with interquartile ranges (IQR); categorical data as counts and percentages. Table 2 comparisons used Mann-Whitney U for continuous and χ² or Fisher exact tests for categorical variables (two sided, P &lt; 0.05). Multivariable logistic regression was used to identify independent predictors of infection.Table 3Infectious Syndromes, Pathogens, and Timing of First Infection Following CRS Onset Results Among 230 CRS cases, median age was 64 yr (IQR 57–70) and 59% were male. Non-Hodgkin lymphoma accounted for 62% and multiple myeloma for 38%. Median prior therapy lines were 3. CRS was grade 1–2 in 97%. CAR-HEMATOTOX was low in 156 (68%) (Table 1). Within 90 days, 51 patients (22%) developed infection; median onset was 15 days (IQR 5–26). Infected patients more often received anakinra (22% vs 8%, p = 0.02) and required ICU care (18% vs 7%, p = 0.05); grade ≥3 CRS trended higher (10% vs 3%, p = 0.06). In multivariable analysis adjusting for age, CAR-HEMATOTOX, ICU admission, and anakinra, both ICU admission (aOR 2.06; 95% CI 0.70–5.81; p = 0.18) and anakinra use (aOR 2.18; 95% CI 0.83–5.53; p = 0.10) were associated with higher infection odds, though not statistically significant. 90-day survival was 88% with infection versus 96% without (p = 0.09) (Table 2). 51 infectious episodes were documented: bacteremia 22; gastrointestinal 9; central line–associated bloodstream infection 7; other sites 22. Bacteria caused 59%, viruses 37% (15 CMV, 4 SARS-CoV-2), and fungi 4%. No infection-related deaths occurred (Table 3). Conclusion Infection was common after CRS, but did not alter early survival. Anakinra exposure and ICU admission were associated with a higher likelihood of infection, though not statistically significant. Targeted surveillance should focus on patients requiring intensified CRS management. Disclosures Yi Lin, M.D., BMS: Board Member|Caribou: Advisor/Consultant|Genentech: Board Member|Jassen: Board Member|Jassen: Steering Committee|Kite/Gilead: Steering Committee|Legend: Board Member|NexImmune: Advisor/Consultant|NexT Therapeutics: Board Member|Pfizer: Board Member|Regeneron: Board Member|Sanofi: Board Member|Tessera: Board Member Paschalis Vergidis, MD, MSc, Current Fungal Infection Reports: Honoraria|F2G: Grant/Research Support|Merck Manuals: Honoraria|Mundipharma: Grant/Research Support|Scynexis: Advisor/Consultant|Scynexis: Grant/Research Support
PART characterization using MK‐6240 and Flortaucipir
Soares, Carolina, Ferreira, Pamela C.L., Madeiros, Marina Scop, Rocha, Andreia, Bellaver, Bruna, Oliveira, Markley Silva , Povala, Guilherme, Amaral, Lívia , Masdeu, Joseph C., Tudorascu, Dana L, Karikari, Thomas K, Soleimani‐Meigooni, David N., Fortea, Juan M., Lowe, VJ, Oh, Hwamee, Pascual, Belen, Gordon, Brian A., Rosa‐Neto, Pedro, Baker, Suzanne L. , Pascoal, Tharick A, Medeiros, Marina Scop , Soares, Carolina , Ruppert, Emma Patrice , Ferreira, Pâmela C.L. , Madeiros, Marina Scop, Rocha, Andreia, Rodrigues, Matheus Scarpatto , Bellaver, Bruna , Povala, Guilherme , Lussier, Firoza Zubeida , Masdeu, Joseph C , Tudorascu, Dana , Karikari, Thomas K. , Soleimani‐Meigooni, David N. , Fortea, Juan , Oh, Hwamee , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 11, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_106723 Get It

Abstract Background Older adults with brain tau pathology but no evident amyloid‐beta (A) pathology can be referred to as primary age‐related tauopathy (PART). However, in vivo characterization of PART using biomarkers remains unclear, varying based on the method used to define tau pathology (e.g. different tau‐PET tracers). Here, we conducted a head‐to‐head characterization of PART using two different tau‐PET tracers. Method We studied 433 individuals from the HEAD cohort (244 CU, 138 MCI, and 51 with dementia). Participants underwent clinical assessments, MRI, A‐PET, both MK‐6240 and Flortaucipir scans, and a subset with plasma biomarkers ( n = 332). A‐PET positivity was defined as Centiloid>24. Tau‐positivity(T) was determined by MK‐6240 and Flortaucipir SUVR values exceeding the mean+2SD in at least one Braak region anchored in CU A‐ individuals followed by visual confirmation in A‐/T+ cases. Concordance across biomarkers was assessed among PART (A‐/T+), A‐/T‐ and A+/T+ groups. Plasma GFAP, p ‐tau217, NFL levels, and Centiloids were compared across A/T groups using linear regression. Result We found a total of 25 (5.8 %) cases classified as A‐/T+ defined by at least one tau tracer (74±6.3 years, 52% females, 17 CU, 3 MCI, 5 with dementia). Detection of A‐/T+ cases varied by tracer: MK‐6240( n = 20), Flortaucipir( n = 16) (Figure 1A). Among A‐/T+ individuals, MK‐6240 identified 13 CU, 4 MCI, and 3 dementia cases, while Flortaucipir identified 11 CU, 3 MCI, and 2 dementia cases(Figure 1B). Concordance between MK‐6240 and Flortaucipir in A‐/T+ cases was low ( n = 11, 44%)(Figure 1C). A‐/T+ individuals showed no significant biomarker differences from A‐/T‐ but had lower biomarker levels than A+/T+: Centiloids (MK‐6240: T=15.08, p <0.001; Flortaucipir: T=14.36, p <0.001), GFAP (MK‐6240: T=5.04, p < 0.01; Flortaucipir: T=2.92, p <0.001), p ‐tau217 (MK‐6240: T=7.77, p <0.001; Flortaucipir: T=6.34, p <0.001), except for NFL (MK‐6240: T=1.35, p = 0.18; Flortaucipir: T=1.14, p = 0.25)(Figure 2). Representative A and tau biomarker cases (Figure 3A), along with discordant cases classified as T+ by only one tracer (Figure 3B), are illustrated. Conclusion Our preliminary analysis revealed a higher prevalence of A‐/T+ cases with MK‐6240 than Flortaucipir, low concordance between tracers and consistently lower biomarker levels in A‐/T+ compared to A+/T+. Larger studies and longitudinal analyses are necessary to ascertain the pathological trajectories of A‐/T+ individuals with varying tau biomarker profiles.
Aβ‐dependent trajectories of Braak stages for MK6240 and Flortaucipir tau PET
Bellaver, Bruna, Povala, Guilherme, Ferreira, Pamela C.L., Amaral, Lívia , Rocha, Andreia, Masdeu, Joseph C. , Tudorascu, DL, Karikari, Thomas K, Soleimani‐Meigooni, David N., Fortea, Juan M., Lowe, VJ, Oh, Hwamee, Pascual, Belen, Gordon, Brian A., Rosa‐Neto, Pedro, Baker, Suzanne L. , Pascoal, Tharick A, Pascual, Belén , Rocha, Andréia Silva da , Pascual, Belen , Bellaver, Bruna , Povala, Guilherme , Ferreira, Pâmela C.L. , Bauer‐Negrini, Guilherme , Lussier, Firoza Zubeida , Rocha, Andreia, Masdeu, Joseph C , Tudorascu, Dana , Karikari, Thomas K. , Soleimani‐Meigooni, David N. , Fortea, Juan , Oh, Hwamee , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 10, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_107040 Get It

Abstract Background Tau accumulation in the brain is postulated to follow a hierarchical pattern, known as Braak staging, originally defined in postmortem brains. PET‐based Braak stages have since been proposed, however, tau PET tracers exhibit distinct binding characteristics that might influence the detectable trajectories of tau accumulation and its relationship with other biomarkers across the AD continuum. In a head‐to‐head study, we investigated the emergence of tau positivity in each Braak region, along with plasma p ‐tau217 and GFAP, as a function of Aβ PET deposition. Method We evaluated 352 individuals from the HEAD study (205 cognitively unimpaired and 147 cognitively impaired) with head‐to‐head Aβ PET, MK6240 and Flortaucipir tau PET, and plasma p ‐tau217 (ALZpath) and GFAP (Quanterix) measures. Tau PET Braak regions, plasma p ‐tau217 and GFAP trajectories were modeled as functions of Aβ burden (Centiloid scale) using the Lowess method. Biomarkers were z‐scored anchored on young individuals ( n = 19, <28 years old). Positivity for plasma biomarkers and for each Braak region was determined when values surpassed 2.5 z‐score from the mean. Result Among the tested markers, plasma GFAP was the earliest to show abnormality as a function of Centiloid, occurring at 11 Centiloids. For MK6240, Braak I was the first regions to became positive (at 22 Centiloids), followed by Braak II (at 32 Centiloids), Braak IV (at 42 Centiloids), Braak III (at 52 Centiloids), Braak V (at 70 Centiloids) and Braak VI (at 123 Centiloid; Figure 1A). For Flortaucipir the first region to became positive was Braak IV (at 50 Centiloids), followed by Braak I and II (both at 56 Centiloids), Braak III (at 85 Centiloids) and Braak V (at 92 Centiloids). Braak VI region did not reach the threshold for positivity in our population (Figure 1B). Plasma p ‐tau217 reached the positivity threshold at 38 Centiloids. Conclusion MK6240 follows a Braak stage‐like pattern of abnormality as a function of Aβ burden, whereas for Flortaucipir, Braak IV is the first region to became abnormal. MK6240 becomes abnormal at lower Aβ burden levels compared to plasma p ‐tau217 and Flortaucipir but after plasma GFAP. Our findings suggest that MK6240 might detect tau pathology in earlier disease stages than Flortaucipir.